Aurobindo Pharma Sees Sharp Open Interest Surge Amid Bullish Momentum

Open Interest and Volume Dynamics

On 31 Aug 2026, Aurobindo Pharma’s open interest (OI) in derivatives rose sharply by 2,962 contracts, an 11.24% increase from the previous day’s 26,354 to 29,316. This rise in OI was accompanied by a volume of 30,674 contracts, indicating robust trading activity. The futures segment alone accounted for a value of approximately ₹28,925.64 lakhs, while the options segment’s notional value stood at an impressive ₹26,090.90 crores, culminating in a total derivatives value of ₹34,422.54 lakhs.

The underlying stock price also reflected this momentum, hitting a new 52-week high of ₹1,700 during intraday trading, marking a 3.32% gain on the day. The stock opened with a gap-up of 3.12%, further reinforcing the bullish undertone. Over the past five consecutive trading sessions, Aurobindo Pharma has delivered a cumulative return of 5.63%, outperforming its sector by 3.62% and the broader Sensex, which declined by 0.43% on the same day.

Market Positioning and Directional Bets

The surge in open interest alongside rising prices typically indicates fresh long positions being established, suggesting that traders are betting on further upside. The fact that Aurobindo Pharma is trading above all major moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — adds technical confirmation to the bullish narrative. This alignment of technical indicators often attracts momentum traders and institutional investors looking to capitalise on sustained upward trends.

However, a notable decline in delivery volume was observed on 28 Aug 2026, with a drop of 41.69% compared to the five-day average delivery volume, which stood at 2.37 lakh shares. This falling investor participation in the delivery segment may imply that while speculative interest is rising in the derivatives market, long-term holding interest is somewhat subdued. Such divergence can sometimes precede short-term volatility or profit-booking phases.

Implications for Investors and Traders

The mid-cap pharmaceutical giant, with a market capitalisation of ₹94,609 crores, currently holds a Mojo Score of 62.0 and a Mojo Grade of Hold, recently downgraded from Buy on 25 May 2026. This reflects a cautious stance amid the recent price rally and open interest surge. Investors should note that while the derivatives market activity points to bullish positioning, the underlying fundamentals and sector dynamics warrant careful monitoring.

Liquidity remains adequate for sizeable trades, with the stock’s average traded value supporting a trade size of approximately ₹2.28 crores based on 2% of the five-day average. This ensures that institutional investors can enter or exit positions without significant market impact, which is crucial for sustaining momentum in the derivatives market.

Technical and Sectoral Context

Aurobindo Pharma’s outperformance relative to the Pharmaceuticals & Biotechnology sector, which declined by 0.31% on the day, highlights its relative strength. The stock’s narrow intraday trading range of ₹3.3 on a day of strong gains suggests controlled buying interest rather than erratic volatility, a positive sign for stability in price discovery.

Given the sector’s sensitivity to regulatory developments and global pharmaceutical trends, the recent surge in open interest may also reflect hedging activity by market participants anticipating upcoming catalysts or earnings announcements. Traders should watch for changes in put-call ratios and strike price concentrations to better gauge the nature of directional bets.

Outlook and Strategic Considerations

While the open interest surge and price breakout signal positive momentum, investors should remain vigilant to potential profit-taking or volatility spikes, especially given the recent downgrade in Mojo Grade from Buy to Hold. The stock’s ability to sustain above key moving averages and maintain volume support will be critical in confirming a durable uptrend.

Market participants may also consider the broader macroeconomic environment, including pharmaceutical sector headwinds such as pricing pressures, regulatory scrutiny, and global supply chain challenges. These factors could influence the sustainability of the current bullish positioning in derivatives.

In summary, Aurobindo Pharma’s derivatives market activity reveals a clear tilt towards bullish bets, supported by strong price action and volume. However, the divergence in delivery volumes and the recent rating adjustment counsel a balanced approach, combining technical momentum with fundamental vigilance.

Key Metrics at a Glance:

• Open Interest: 29,316 contracts (up 11.24%)
• Volume: 30,674 contracts
• Futures Value: ₹28,925.64 lakhs
• Options Value: ₹26,090.90 crores
• Underlying Price: ₹1,693
• 52-Week High: ₹1,700
• Market Cap: ₹94,609 crores (Mid Cap)
• Mojo Score: 62.0 (Hold, downgraded from Buy)
• 5-Day Consecutive Gains: 5.63% cumulative return

Investors and traders should continue to monitor open interest trends, volume patterns, and price action in conjunction with sector developments to make informed decisions on Aurobindo Pharma’s stock and derivatives positions.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →